Mark, Michael
Boehringer Ingelheim (Germany)
3 papers on CoChatORCID 0000-0002-8284-5773
Most cited papers
- Verified
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care
Diabetes Treatment and ManagementCardiovascular Function and Risk Factors
Cited by 975
- Verified
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism
Diabetes Treatment and ManagementMetabolism, Diabetes, and Cancer
Cited by 608
- Verified
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition
Tomita, I., Kume, S., Sugahara, S., Osawa, N., Yamahara, K., Yasuda-Yamahara, M., Takeda, N., Chin-Kanasaki, M., Kaneko, T., Mayoux, E., et al. (2020) · Cell Metabolism
Chronic Kidney Disease and DiabetesAcute Kidney Injury Research
Cited by 376
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free